UBE2O and hepatocellular carcinoma: Ubiquitin Conjugating Enzyme E2O (UBE2O) has been found to be significantly correlated with the prognosis of hepatocellular carcinoma (HCC), and UBE2O is considered a potential therapeutic target in various types of cancer [13, 18–26].